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regions where re-use exceeded 15% (US$55.5 versus
US$791.5) and in regions where HIV prevalence exceeded
1% (US$13.29 versus US$434.1). Uncertainty analysis
identiﬁed the HIV-attributable fraction and the number
of syringes and needles required as key sources of uncer-
tainty. CONCLUSION: Safe and appropriate use of injec-
tion policies are cost-effective, particularly in countries
where re-use of injection equipment is common or where
the HIV epidemic is generalized.
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OBJECTIVES: We measured adherence to and satisfac-
tion with anti-HIV treatment and quality of life (QoL) of
a sample of Italian patients (pts). METHODS: We carried
out a perspective, multicentre observational survey. Pts
who needed a simpler antiretroviral treatment were 
asked to ﬁll in both a questionnaire for measuring 
adherence/satisfaction with therapy (PMAQ-7) and a
QoL one (MOS-HIV). Questionnaires were administered
at baseline (change of therapy) and 3 months later.
RESULTS: From March to December 2001, 45 centres
enrolled 407 pts (285 fully evaluable). Males were
69.5%, mean age was 38 years. HIV infection was mainly
due to IV drug use (44%) and heterosexual intercourse
(36%). Baseline treatments were: 2NRTI + 1 or more PI
(68%), 2NRTI + 1NNRTI (12%), 3NRTI (10%), other
(10%). Treatments changed as follow: 2NRTI + 1 or
more PI (20%), 2NRTI + 1NNRTI (33%), 3NRTI (43%;
in this group 102 out of 122pts, 84%, on Trizivir), other
(5%). Reasons for changing therapy (multiple reasons
allowed) were high pill burden (45%), side effects (29%),
high number of assumptions (26%), failure due to poor
compliance (18%), dietary requirements (17%), ﬁxed
time of assumption (12%), other (13%). After switching,
scores of both questionnaires increased in all pts, meaning
better compliance and QoL. Effect sizes (ES) of PMAQ-
7 score showed that the highest values were related to
PMAQ-7 adherence (0.28) and scheduling (0.75); highest
values were reported in scheduling among pts treated
with 3NRTI (ES 1.01). Highest ES of MOS-HIV were in
health transition (0.5) and MOS-HIV QoL (0.38); highest
values were reported in health transition among pts
treated with 3NRTI (ES 0.69). CONCLUSIONS: We con-
clude that a simpler therapy could improve both HIV
patient adherence and QoL.
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OBJECTIVES: To critically review available instruments
for assessing quality of life (QoL) and health-related QoL
(HRQL) in HIV and AIDS, with speciﬁc reference to suit-
ability for clinical trials. METHODS: Literature searches
were conducted using Medline, AIDSLine and PsycINFO
to identify instruments used to measure QoL or HRQL
in HIV and/or AIDS since 1990. Relevant literature per-
taining to such measures was critically reviewed. Instru-
ments were appraised according to the following issues:
development (theoretical basis, content derivation); psy-
chometric properties (dimensionality, test-retest reliabil-
ity, internal consistency, face/content validity, construct
validity, responsiveness); practicality for clinical trials
(length, complexity, method/ease of administration and
scoring); cultural considerations (language availability,
cross-cultural validity, translation/adaptation methodol-
ogy); and application in HIV/AIDS populations (study
type, sample characteristics). RESULTS: Sixteen instru-
ments were selected for review; 5 HIV/AIDS-speciﬁc
(HAT-QoL, MQoL-HIV, LWHIV, HIV-QL31, FQLS), 
3 adaptations of cancer-speciﬁc instruments (HOPES,
FAHI, QLQ-C30 + HIV Module), 3 adaptations of
generic instruments (MOS-HIV, HIV-PARSE, AIDS-
HAQ), and the 5 most commonly employed generic
instruments in HIV/AIDS (SF-36, SF-20, QWB, EQ-5D,
QL-Index). Overall, the conceptual quality of the instru-
ments reviewed was poor, with most lacking a theore-
tical model of the intended construct. As such, none of
the instruments measure QoL, with most assessing the
various dimensions of HRQL. The content of most of the
instruments was derived without reference to patients
with HIV/AIDS and, thus, would have limited applica-
bility to this patient group. The HAT-QoL, MQoL-HIV
and FAHI comprised items that appeared better targeted
to the issues of relevance to patients with HIV or AIDS.
However, the psychometric properties of the HAT-QoL
and MQoL-HIV were poor. CONCLUSIONS: Of the
instruments reviewed, the FAHI appears to be the most
appropriate instrument for measuring HRQL in clinical
trials. However, a number of its properties have yet to be
adequately assessed (including face/content validity, test-
retest reliability and unidimensionality of its scales).
